The purpose of NEI's Translational Research program (TRP) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system.The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to four years and will support research that is in the final states of preclinical development with potential for near-term clinical development. The total duration of both R61 and R33 cannot exceed five years. The R33 is to focus on advancing a single therapeutic candidate through Investigational New Drug or Investigational Device Exemption (IND/IDE) enabling studies, filing an IND/IDE package with the FDA, and designing future clinical trials. R33 recipients must submit or obtain an IND/IDE application to FDA, or must transition the product to clinical practice, within the period of performance. The specific activities appropriate for the R33 phase will depend on the product under study and available preliminary data on the product. Delineation of milestones by the applicant for the R61 and R33 phases is a key characteristic of this program. A milestone is defined as a scheduled event in the project timeline that signifies the completion of a major project stage or activity. This program will support applications that propose a series of milestones including manufacturing and product development goals. Applications that address contingency plans to proactively confront potential delays in meeting the milestones are strongly encouraged. Milestones are required for both phases. Milestones must be specific, measurable, achievable, relevant, and time-bound (SMART). All projects will begin with a R61 phase regardless of therapeutic starting point.
NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health lists this opportunity for nonprofit applicant type listed. Review the coded eligibility, award range, source synopsis, and official notice before deciding whether to apply.
Deadline
November 16, 2029
1122 days remaining
Award range
—
official range may be incomplete
Applicant signal
Nonprofit applicant type listed
the official notice controls eligibility
- 00 — State governments
- 01 — County governments
- 02 — City or township governments
- 04 — Special district governments
- 05 — Independent school districts
- 06 — Public and state-controlled institutions of higher education
- 07 — Federally recognized Native American tribal governments
- 08 — Public housing authorities and Indian housing authorities
- 11 — Native American tribal organizations other than federally recognized tribal governments
- 12 — 501(c)(3) nonprofits other than institutions of higher education
- 13 — Nonprofits without 501(c)(3) status other than institutions of higher education
- 20 — Private institutions of higher education
- 22 — For-profit organizations other than small businesses
- 23 — Small businesses
- 25 — Other applicants; see the official eligibility clarification
These are high-level Grants.gov codes. Additional eligibility text, geographic restrictions, and program-specific rules in the official notice can narrow them.
- Confirm entity eligibility in the full Notice of Funding Opportunity.
- Check SAM.gov and Grants.gov registration requirements and timing.
- Read every attachment for matching, cost-share, geography, and award conditions.
- Verify the exact deadline time and any agency-specific submission portal.
Want the opportunities that fit your work?
FunderFit compares your program with live federal opportunities and application-ready foundations, then delivers a ranked, source-labeled shortlist.
Source: Grants.gov daily XML extract, 2026-10-21 extract. This page reproduces selected public listing fields for research convenience. The official Notice of Funding Opportunity and agency instructions control. This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services.